Open AccessUse of Broncho-Munal after measles vacc ination inkids with recu rrent infections
Author(s) -
С. М. Харит,
Е. П. Начарова,
С. П. Каплина,
Н Е Монахова,
О. В. Голева,
N E Monahova
Publication year - 2011
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja795
Subject(s) - vaccination , medicine , measles , immunology , titer , leukopenia , antibody , pediatrics , chemotherapy
15 kids (1-3 years old) with recurrent infections received therapy with Broncho-munal (1 capsule/day)from the day 1 till the day 30 after measles vaccination. The control group of 29 kids of the same age did notreceive any immunomodulatory therapy after the vaccination. 12 out of 15 (80%) kids in the Broncho-munalgroup developed no complications after the vaccination compared with 20 out of 29 kids (68,9%) in the controlgroup. The frequency of intercurrent infections was 3,5 times lower in the Broncho-munal group. The kids inthe Broncho-munal group developed neither lymphopenia nor leukopenia. They had increased counts of CD25+and CD20+ cells by the day 30 after the vaccination, prolonged production of the specific antibodies as well ashigher geometric mean titers of the anti-measles antibodies on the day 45 after the vaccination. Taken togetherthese observations suggest that Broncho-munal protected from the transitory immunosuppressive effects ofthe vaccination.